<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294774</url>
  </required_header>
  <id_info>
    <org_study_id>CKRP203A2202</org_study_id>
    <secondary_id>2010-019689-10</secondary_id>
    <nct_id>NCT01294774</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus</brief_title>
  <official_title>A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of KRP203 in clinically active subacute
      cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard
      treatment, such as antimalarials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of KRP203 in reduction of severity of symptoms, as measured using the activity score of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of oral KRP203 in patients with subacute cutaneous lupus erythematosus</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state blood concentrations of KRP203 and KRP203-Phosphate (KRP203-P) in SCLE patients</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the activity of SCLE using visual analogue scales for global skin health as assessed by the physician and the patient</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the systemic features of SCLE using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Subacute Cutaneous Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>KRP203 - 1.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to KRP203 - 1.2 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP203 - 1.2mg</intervention_name>
    <arm_group_label>KRP203 - 1.2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to KRP203 - 1.2 mg</intervention_name>
    <arm_group_label>Placebo to KRP203 - 1.2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients,18 to 65 years of age inclusive, who have been defined as
             having SCLE based on the typical clinical picture and the characteristic
             histopathological features as described by Sontheimer et al. at least three months
             before study entry (screening)

        Exclusion Criteria:

          1. Patients with preexisting nephritis, central nervous or pulmonary involvement or any
             major internal organ damage, either related or unrelated to lupus, which are deemed by
             the Investigator to be clinically significant. Patients having signs or symptoms of
             other autoimmune diseases such as systemic lupus erythematosus or Sjogren`s syndrome
             are allowed to enter the study at the Investigator`s discretion.

          2. Patients who have been treated with:

               -  immunoglobulins and/or monoclonal antibodies within 6 months prior to
                  randomization.

               -  rituximab, cyclophosphamide, or other immunosuppressive treatments with effects
                  potentially lasting over 6 months, within 12 months prior to randomization.

               -  a medium or high dose (â‰¥ 1 mg prednisone or equivalent per body weight kg)
                  corticosteroid therapy in the last 8 weeks prior to randomization.

               -  antimalarial agents (hydroxychloroquine, chloroquine or quinacrine) in the last 6
                  weeks prior to randomization.

               -  biologic therapies, such as etanercept, within the last 4 weeks prior to
                  randomization.

               -  any other immunosuppressive or immunomodulatory therapy such as methotrexate,
                  azathioprine, cyclosporin A or mycophenolate, thalidomide, retinoids or dapsone
                  in the last 4 weeks prior to randomization.

               -  total lymphoid irradiation or bone marrow transplantation.

          3. Pregnant, planning to get pregnant, and/or lactating females or males planning to
             father a child within time period of the study or subsequent exclusionary period.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>161 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=10083</url>
    <description>Results for CKRP203A2202 from Novartis Clinical Trial Results website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus erythematosus</keyword>
  <keyword>skin lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

